La Jolla Pharmaceutical (LJPC) Stock Price, News & Analysis

Company Overview

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts.

Key Stats

• Today's Range: N/A
• 50-Day Range: $3.12 to $6.22
• 52-Week Range: N/A
• Volume: 66,708 shs
• Average Volume: 158,476 shs
• Market Capitalization: $155.11 million
• P/E Ratio: 51.84
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

La Jolla Pharmaceutical Stock Analysis - MarketRank™

La Jolla Pharmaceutical scored higher than 46% of companies evaluated by MarketBeat, and ranked 682nd out of 973 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for La Jolla Pharmaceutical.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 475.00%

Earnings Growth

Earnings for La Jolla Pharmaceutical are expected to grow by 475.00% in the coming year, from $0.04 to $0.23 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of La Jolla Pharmaceutical is 51.84, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 137.62.

Price to Earnings Ratio vs. Sector

The P/E ratio of La Jolla Pharmaceutical is 51.84, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 137.22.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for LJPC.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

La Jolla Pharmaceutical does not currently pay a dividend.

Dividend Growth

La Jolla Pharmaceutical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 2.5 / 5
• Environmental Score: -2.77

Short Interest

There is no current short interest data available for LJPC.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for La Jolla Pharmaceutical this week, compared to 0 articles on an average week.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, La Jolla Pharmaceutical insiders have not sold or bought any company stock.

Percentage Held by Insiders

36.30% of the stock of La Jolla Pharmaceutical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

97.06% of the stock of La Jolla Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LJPC Stock Analysis - Frequently Asked Questions

How were La Jolla Pharmaceutical's earnings last quarter?

La Jolla Pharmaceutical (NASDAQ:LJPC) released its earnings results on Monday, May, 16th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of $0.01 by $0.16. The biopharmaceutical company earned $10.43 million during the quarter, compared to the consensus estimate of $13.10 million. La Jolla Pharmaceutical had a net margin of 8.54% and a negative trailing twelve-month return on equity of 5.46%.

What other stocks do shareholders of La Jolla Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that La Jolla Pharmaceutical investors own include BioCryst Pharmaceuticals (BCRX), El Pollo Loco (LOCO), Intercept Pharmaceuticals (ICPT), Bristol-Myers Squibb (BMY), Exelixis (EXEL), Sarepta Therapeutics (SRPT) and Inovio Pharmaceuticals (INO).

Company Calendar

• Last Earnings: 5/16/2022
• Today: 11/15/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:LJPC
• CUSIP: N/A
• CIK: 920465
• Web: www.lajollapharmaceutical.com
• Phone: (617) 715-3600
• Fax: 858-626-2851
• Employees: 61
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): $0.12
• Trailing P/E Ratio: 51.84
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $19.66 million
• Net Margins: 8.54%
• Pretax Margin: 8.64%
• Return on Equity: -5.46%
• Return on Assets: 4.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.02
• Quick Ratio: 3.52

Sales & Book Value

• Annual Sales: $75.72 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 7.95
• Book Value: ($2.94) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 24,937,000
• Free Float: 15,885,000
• Market Cap: $155.11 million
• Optionable: Optionable
• Beta: 2.39